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Abstract Myeloid-derived suppressor cells (MDSCs) are
originated and differentiated population from common
hematopoietic progenitor cells. Generally, in the late stage
of inflammation, MDSCs differentiation and expansion are
promoted to suppress the over-activated immune system so
that the immune system can maintain the homeostasis.
Recently, it has been revealed that MDSCs accumulate in
cancer patients and tumor-bearing experimental animals,
and these tumor-derived MDSCs suppress anti-tumor
immunity by secreting immunosuppressive cytokines
including reactive oxygen species and inducible nitric
oxide synthase. This fact prompts scientists to shed light on
MDSCs as significant targets for anti-cancer immunother-
apy. However, due to morphological, phenotypic, and
functional heterogeneities of MDSCs, it is not easy to
develop therapeutic strategies targeting MDSCs. In this
review, we will summarize recent progress on defined
subsets of MDSCs and their strategies to suppress T cell-
mediated anti-tumor immunity.
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The discovery of MDSCs
MDSCs appeared to the scientific field in the late 1970s
(Strober 1984; Holda et al. 1985; Ribechini et al. 2010). At
that time, this was just a formerly unknown immune cell
population which possesses immunosuppressive features,
but it was enough to attract scientists. Firstly, MDSCs were
isolated from bone marrow and spleens from tumor-chal-
lenged mice, and it was revealed that those isolated cells
were able to suppress T cell responses both in vivo and
in vitro against tumor cells (Roder et al. 1978; Subiza et al.
1989). Because of its immunosuppressive functions and
immature status, MDSCs were also called as natural sup-
pressor cells, immature myeloid cells, and myeloid sup-
pressor cells. Finally, the naming issue has been fixed by
Gabrilovich and his colleagues in 2007 as they suggest the
unification of the name: ‘‘MDSC’’ which is reflecting both
origin of those cells and the function after 37 years of its
discovery (Gabrilovich et al. 2007). From that point,
MDSCs are uprising as a novel immune cell population
that regulates innate and adaptive immunity by inactivating
T cells. Studies for MDSCs have been accelerated since
2000, but many things about MDSCs are behind the veil
and waiting for being elucidated.
The subsets of MDSCs
Under the united name of MDSC, many subsets of MDSCs
have been defined, and these various subsets reflect the
heterogeneity and complexity of MDSCs. At first, MDSCs
were defined as cells which express Gr-1?CD11b? as cell
surface molecules but not express the typical expression
marker of mature macrophages and dendritic cells (DC) in
mice (Bronte et al. 1998). With specific antibodies that
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recognize the surface molecules of MDSCs (Talmadge and
Gabrilovich 2013), mouse MDSCs are classified as two
major subsets of MDSCs: granulocytic MDSCs (G-
MDSCs) have similar morphologies with granulocytes and
monocytic MDSCs (M-MDSCs) have similar morpholo-
gies with monocytes (Sica and Bronte 2007; Movahedi
et al. 2008). Generally, G-MDSCs are distinguished as they
express CD11b?Ly6G?Ly6Clow, while M-MDSCs express
CD11b?Ly6Glow/-Ly6Chigh on their surfaces (Movahedi
et al. 2008; Youn et al. 2008). Unlike mice, human MDSCs
do not express Gr-1. Instead, human MDSCs are charac-
terized as CD11b?CD33?HLA-DR-. Furthermore,
CD15?CD11b?CD33?HLA-DR- population corresponds
to G-MDSCs, and CD14?CD11b?CD33?HLA-DR- pop-
ulation corresponds to M-MDSCs (Nagaraj and Gabrilo-
vich 2010; Greten et al. 2011; Dumitru et al. 2012;
Filipazzi et al. 2012; Poschke and Kiessling 2012; Meirow
et al. 2015). Until now, there are many subsets that are not
clarified because of their ambiguous expression levels of
surface molecules like Ly6G and Ly6C. Thus, it is not easy
to exactly classify them into G-MDSCs or M-MDSCs.
Many of these intermediate subsets of MDSCs are still
discovering.
Recently, fibrocytic MDSCs (F-MDSCs) are character-
ized as a novel MDSC subset in human (Abrams and
Waight 2012; Zhang et al. 2013; Mazza et al. 2014; Zoso
et al. 2014; Gunaydin et al. 2015). F-MDSCs show tumor-
associated circulating fibrocyte phenotypes and have T
cell-mediated immunosuppressive functions. F-MDSCs
seem to express CD11blowCD11clowCD33?IL-4Ra? on
their surfaces (Mazza et al. 2014; Gunaydin et al. 2015).
According to Zhang et al. (2013), F-MDSCs might express
HLA-DR unlike other human MDSCs. Although it is clear
that F-MDSCs with fibrocytic phenotypes show immuno-
suppressive functions, little is known how F-MDSCs dif-
ferentiate from common HSCs and suppress T cells.
On the other hand, it is still unclear what factors drive
MDSC differentiation into two or more different subsets
from same precursor cells. It was revealed that tumor-in-
duced granulocyte colony-stimulating factor (G-CSF) is
one of those factors (Waight et al. 2011; Abrams and
Waight 2012; Luyckx et al. 2012; Kawano et al. 2015). Our
recent study also showed that the serum G-CSF level is
associated with the inhibition of expansion and differenti-
ation of G-MDSCs in tumor-bearing adiponectin knockout
mice (Han et al. 2013). Nonetheless, the mechanism and
crucial factors that drive the differentiation from common
progenitor cells into various types of MDSC subsets should
be further elucidated and identified.
The immunosuppressive functions of G-MDSCs
MDSCs produce immunosuppressive factors such as reac-
tive oxygen species (ROS), inducible nitric oxide synthase
(iNOS), arginase 1, and IL-10 to suppress the proliferation
or activities of anti-cancer T cells or macrophages (Fig. 1).
Basically, arginase produces urea and ornithine from
arginine, which leads to depletion of arginine. In turn,
MDSCs suppress the proliferation of T cells effectively,
because arginine is a key nutritional substrate for T cell
proliferation (Ochoa et al. 2007; Munder 2009; Rodriguez
et al. 2009). MDSCs also secret immunosuppressive
cytokine IL-10, which leads to immunosuppressive regu-
latory T cells (Treg) activation as well as the induction of
the anti-inflammatory M2 macrophage differentiation, and
the expansion of MDSC population by tumor growth
contribute to immune escape of tumor cells through these
suppressive effects of IL-10 (Sinha et al. 2007; Heim et al.
2015). Besides of these common suppressive mechanism
including arginase expression and IL-10 secretion,
G-MDSCs tend to primarily use ROS as the mechanism for
Fig. 1 Strategies of G-, M-, and
F-MDSCs for T cell
suppression. MDSC myeloid-
derived suppressor cell, G-
MDSC granulocytic MDSC, M-
MDSC monocytic MDSC, F-
MDSC fibrocytic MDSC, ROS
reactive oxygen species, iNOS
inducivle nitric oxide synthase,
NO nitric oxide, IL-10
interleukin 10, IDO indoleamine
oxidase, TCR T cell receptor,
Treg regulatory T cell, M2 u
M2 macrophage
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immune suppression (Kusmartsev et al. 2004; Sinha et al.
2005; Nagaraj et al. 2007; Nefedova et al. 2007; Ando et al.
2008; Markiewski et al. 2008; Youn et al. 2008; Corzo
et al. 2009). G-MDSCs-produced ROS inhibits the antigen-
specific T cell responses by disrupting the physical inter-
action between T cell receptors (TCRs) on T cells and
peptide/major histocompatibility complexes (MHCs) on
antigen presenting cells (Kusmartsev et al. 2004; Nagaraj
et al. 2007; Meirow et al. 2015). Moreover, G-MDSCs-
produced ROS reacts with NO, which leads to the pro-
duction of peroxynitrite. Then, the resulted peroxynitrite
strongly induces the nitration of TCRs followed by the
apoptosis of T cells (Nagaraj et al. 2007; Corzo et al. 2009;
Raber et al. 2014). This finding suggests that G-MDSCs
contribute to develop tumor-specific T cell tolerance.
The immunosuppressive functions of M-MDSCs
While G-MDSCs use ROS as the effector of immune
suppression, M-MDSCs primarily utilize iNOS, arginase,
and IL-10 (Bronte and Zanovello 2005). Similar to arginase
which depletes arginine as T cell nutrient, iNOS produces
NO and citrulline from arginine, and eventually T cell
proliferation is inhibited by arginine depletion. Besides of
arginine depletion, iNOS-induced NO also downregulates
JAK3/STAT5 signaling which is crucial molecular sig-
naling for T cell survival by reducing the phosphorylation,
leading to the apoptosis of T cells (Rodriguez and Ochoa
2008; Dilek et al. 2012). In addition to iNOS and arginase,
IL-10 produced from M-MDSCs also contributes to the
interruption of T cell activation by inducing Foxp3?Treg
(Huang et al. 2006; Serafini et al. 2008). Given that
M-MDSCs can effectively suppress T cells by humoral
action with their immunosuppressive cytokines, physical
interaction between M-MDSCs and T cells may be less
required than G-MDSCs.
The immunosuppressive functions of F-MDSCs
Zhang et al. reported that hematopoietic stem cells (HSC)-
derived fibrocytes suppress T cell proliferation through
indoleamine oxidase (IDO) production, and that those
immunosuppressive fibrocytes are suggested as a novel
MDSC subset (Zhang et al. 2013). In 2014, Zoso et al.
named this population as F-MDSCs and showed that the
physical interaction between F-MDSCs and T cells induces
the production of IDO in F-MDSCs and that F-MDSCs-
produced IDO promotes the expansion of immunosup-
pressive Foxp3 ? Treg cells (Zoso et al. 2014). Previous
study showed that tryptophan is an essential amino acid for
T cell proliferation and activation, and that IDO depletes
tryptophan by degrading it to formylkynurenine, which
leads to the inhibition of T cell proliferation during anti-
gen-specific T cell activation in turn (Lee et al. 2002,
Zhang et al. 2013). Besides of this previously known
tryptophan depletion mechanism, Zoso et al. also showed
that 3-hydroxyanthranilic acid, a downstream metabolite
for IDO-mediated tryptophan degradation, promotes Treg
differentiation by inducing the secretion of immunosup-
pressive transforming growth factor-b from DCs. (Baban
et al. 2009, Yan et al. 2010, Zoso et al. 2014). Therefore, it
is conceivable that F-MDSCs-produced IDO is a major
immunosuppressive molecule to suppress T cells.
Expansion and activation of MDSCs
Mature lymphocytes are originated from the differentiation
of HSCs (Fig. 2) (Sica and Bronte 2007). Under infection
or tumor-bearing condition, the HSC differentiation into
mature immune cells is unfinished and remained as less
differentiated cells, MDSCs (Bronte et al. 2000). This
special condition prepares the expansion and accumulation
of MDSCs. Then the issue is rising up: do tumors regulate
the expansion and accumulation of MDSCs? The answer is
yes. MDSCs are expanded and activated by tumor-driven
cytokines including stem cell factor (SCF), G-CSF, mac-
rophage colony-stimulating factor (M-CSF), granulocyte–
macrophage colony-stimulating factor (GM-SCF), and
vascular endothelial growth factor, IL-4, and IL-6. Those
cytokines activate signal transducer and activator of tran-
scription 3 (STAT3) which is the key molecule of the
expansion and activation of MDSCs (Condamine and
Gabrilovich 2011). Cytokine-activated STAT3 upregulates
the transcription of gene set related to the expansion and
immunosuppressive activity of MDSCs. STAT3 activation
upregulates the transcriptions of calcium-binding pro-
Fig. 2 Tumor-mediated MDSC formation. G-CSF granulocyte col-
ony-stimulating factor, GM-CSF granulocyte macrophage colony-
stimulating factor, M-CSF macrophage colony-stimulating factor, IL-
6 interleukin 6, HSC hematopoietic stem cell,MDSC myeloid-derived
suppressor cell, ROS reactive oxygen species, iNOS inducible nitric
oxide synthase, IL-10 interleukin 10, Treg regulatory T cell
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inflammatory proteins S100A8 and S100A9 (Foell et al.
2007) in HSCs. In turn, the increase in S100A8 and
S100A9 inhibits dendritic cell differentiation and promotes
the MDSC expansion, accumulation, and the recruitment
the MDSCs to the tumor site (Cheng et al. 2008). CCAAT-
enhancer-binding protein b which is reported as a crucial
factor for the MDSC expansion is also upregulated by
STAT3 (Marigo et al. 2010). In addition, STAT3 increases
the transcription of p47phox which is a component of
nicotinamide adenine dinucleotide phosphate oxidase
(NOX2). Concerning that NOX2 directly increases ROS, it
is certain that STAT3 positively regulates the immuno-
suppressive activities of MDSCs as well as expansion of
MDSCs (Corzo et al. 2009).
Conclusion
The nature of MDSCs is to terminate or suppress exces-
sively activated immune system so that the immune sys-
tems can be back to the peaceful state after inflammation
reaction. This homeostatic immune regulation device
contributes to protect our body from autoimmunity. How-
ever, due to their immune suppressive roles, tumors easily
pervert MDSCs to build up the tumor-friendly environment
through the inhibition of T cells and the activation of M2
macrophages and Treg cells. Recently, it has been revealed
that MDSCs would suppress the homing of tumor antigen-
specific T cells to tumor site by reducing the expression of
L-selectin on the surfaces of T cells (Hanson et al. 2009).
The novel mechanism that MDSCs prepare tumor-favor
environment is unveiling. These accumulating reports
support the fact that reducing numbers and interfering
functions of MDSCs would be good strategies for the
development of anti-cancer therapy in the near future.
Therefore, to put this forward, elucidating and under-
standing of full story of MDSCs is required to use these
‘double-edged swords’ in a smart way.
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